Grant: Discovery Grants Program - Individual
McMaster University
$55,000.00
Development of a New Platform Technology for Rapid Diagnosis of Human Disease
EF 2024-25
Résumé
Background: Over the past 20 years my research program has focused on the use of functional nucleic acids (DNA aptamers and DNAzymes) as molecular recognition elements for rapid diagnostic applications. Recently, we reported the first example of the direct selection of an RNA-cleaving DNAzyme (RCD) for a specific protein target, eosinophil peroxidase (EPX), which is a biomarker for eosinophilic asthma. The RCD was used to produce both fluorescence and lateral flow assays for rapid detection of EPX in patient sputum samples to diagnose airway eosinophilia. Our long-term goal is to understand the factors leading to successful selection of protein-activated RCDs, and to use this knowledge to develop several new RCDs and associated diagnostic tests for protein markers of human disease.
Key Objectives: Our key objectives for the next 5 years are as follows:
1) Evaluate Impact of Protein Targets on Selection of RCDs. We will perform selection of RCDs for several native or recombinant proteins of varying size, charge and complexity (tertiary and quaternary structure), with varying post translational modifications, or association with a cell membrane, to determine their impact on the success of in vitro selection. We will also assess whether proteins with known aptamers or known association with nucleic acids (RNAses, transcription factors) may lead to higher success with selection.
2) Evaluate Impact of Selection Protocol. To improve selection outcomes, we will modify the selection protocol in several ways, including: varying the selection buffers and time; implementing magnetic bead-based selection methods, and modifying the counter selection media and protocols to determine the impact of each factor on selection outcomes.
3) Investigate Impact of Modified DNA Libaries. The DNA library is likely to be a key factor impacting the success of selection. To investigate this factor, we will evaluate alternative libraries with pre-structured elements that mimic the secondary structure of final RCDs, integrate known aptamer sequences into RCD libraries to bias selection for a desired target; and investigate whether our RCDs are composed of separate binding, communication and catalytic domains, which might allow binding domains (i.e., aptamers) to be swapped with different aptamers to alter the target binding properties of an RCD, which may be optimized with a minimal number of rounds of reselection.
4) Develop RCD based Assays. As new RCDs are developed, we will develop simple fluorescence and lateral flow assays using proven approaches and will evaluate these using appropriate spiked samples.
Novelty and Significance: Overall, this program will provide new insights to aid in more rapid and robust development of the new class of protein-activated RCDs, providing important knowledge that can expand the use of these new molecular recognition elements for applications including rapid clinical diagnosis of both chronic and infectious diseases.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2024-05666
Name nom
Brennan, John
Department département
Biointerfaces Institute
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
55000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Development of a New Platform Technology for Rapid Diagnosis of Human Disease
Keywords
rna-cleaving dnazymes (rcds); protein-selective rcds; in vitro selection methods; alternative rcd libraries; automated selection methods; point-of-care diagnostics; lateral flow devices; fluorescence assays; infectious disease diagnostics; chronic disease diagnostics
Application summary
Background: Over the past 20 years my research program has focused on the use of functional nucleic acids (DNA aptamers and DNAzymes) as molecular recognition elements for rapid diagnostic applications. Recently, we reported the first example of the direct selection of an RNA-cleaving DNAzyme (RCD) for a specific protein target, eosinophil peroxidase (EPX), which is a biomarker for eosinophilic asthma. The RCD was used to produce both fluorescence and lateral flow assays for rapid detection of EPX in patient sputum samples to diagnose airway eosinophilia. Our long-term goal is to understand the factors leading to successful selection of protein-activated RCDs, and to use this knowledge to develop several new RCDs and associated diagnostic tests for protein markers of human disease.
Key Objectives: Our key objectives for the next 5 years are as follows:
1) Evaluate Impact of Protein Targets on Selection of RCDs. We will perform selection of RCDs for several native or recombinant proteins of varying size, charge and complexity (tertiary and quaternary structure), with varying post translational modifications, or association with a cell membrane, to determine their impact on the success of in vitro selection. We will also assess whether proteins with known aptamers or known association with nucleic acids (RNAses, transcription factors) may lead to higher success with selection.
2) Evaluate Impact of Selection Protocol. To improve selection outcomes, we will modify the selection protocol in several ways, including: varying the selection buffers and time; implementing magnetic bead-based selection methods, and modifying the counter selection media and protocols to determine the impact of each factor on selection outcomes.
3) Investigate Impact of Modified DNA Libaries. The DNA library is likely to be a key factor impacting the success of selection. To investigate this factor, we will evaluate alternative libraries with pre-structured elements that mimic the secondary structure of final RCDs, integrate known aptamer sequences into RCD libraries to bias selection for a desired target; and investigate whether our RCDs are composed of separate binding, communication and catalytic domains, which might allow binding domains (i.e., aptamers) to be swapped with different aptamers to alter the target binding properties of an RCD, which may be optimized with a minimal number of rounds of reselection.
4) Develop RCD based Assays. As new RCDs are developed, we will develop simple fluorescence and lateral flow assays using proven approaches and will evaluate these using appropriate spiked samples.
Novelty and Significance: Overall, this program will provide new insights to aid in more rapid and robust development of the new class of protein-activated RCDs, providing important knowledge that can expand the use of these new molecular recognition elements for applications including rapid clinical diagnosis of both chronic and infectious diseases.